| scholarly article | Q13442814 |
| P50 | author | Luis Martinez-Sobrido | Q55189492 |
| Aitor Nogales | Q56528198 | ||
| P2093 | author name string | David J Topham | |
| Marta L DeDiego | |||
| P2860 | cites work | Mutations at alternative 5' splice sites of M1 mRNA negatively affect influenza A virus viability and growth rate | Q36949707 |
| Efficacy and safety of a live attenuated influenza vaccine in adults 60 years of age and older | Q38378644 | ||
| Generation of Recombinant Influenza Virus from Plasmid DNA | Q39664696 | ||
| Splicing of influenza A virus NS1 mRNA is independent of the viral NS1 protein | Q39697237 | ||
| 2A peptides provide distinct solutions to driving stop-carry on translational recoding. | Q42546456 | ||
| Superiority of live attenuated compared with inactivated influenza A virus vaccines in older, chronically ill adults | Q44955734 | ||
| Mechanism of protective immunity against influenza virus infection in mice without antibodies | Q45756709 | ||
| Sequence of interrupted and uninterrupted mRNAs and cloned DNA coding for the two overlapping nonstructural proteins of influenza virus | Q45791146 | ||
| Live attenuated versus inactivated influenza vaccine in infants and young children. | Q55043222 | ||
| Identification of sequence changes in the cold-adapted, live attenuated influenza vaccine strain, A/Ann Arbor/6/60 (H2N2) | Q64129941 | ||
| Emerging roles for the influenza A virus nuclear export protein (NEP) | Q21089600 | ||
| Identification of a novel splice variant form of the influenza A virus M2 ion channel with an antigenically distinct ectodomain | Q27341132 | ||
| Influenza: evolving strategies in treatment and prevention | Q28299371 | ||
| Replication-competent fluorescent-expressing influenza B virus | Q28387786 | ||
| Influenza A virus attenuation by codon deoptimization of the NS gene for vaccine development | Q28395006 | ||
| The annual impact of seasonal influenza in the US: Measuring disease burden and costs | Q29030744 | ||
| Toward a universal influenza virus vaccine: prospects and challenges | Q30223478 | ||
| Plasmid-only rescue of influenza A virus vaccine candidates. | Q30329368 | ||
| Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. | Q30342179 | ||
| A review of vaccine research and development: human acute respiratory infections. | Q30351377 | ||
| Cellular immune correlates of protection against symptomatic pandemic influenza. | Q30353819 | ||
| Influenza A and B virus intertypic reassortment through compatible viral packaging signals. | Q30364518 | ||
| PB1-F2 expression by the 2009 pandemic H1N1 influenza virus has minimal impact on virulence in animal models | Q30385984 | ||
| Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis | Q30408691 | ||
| Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans | Q30412301 | ||
| Influenza virus m2 ion channel protein is necessary for filamentous virion formation | Q33826913 | ||
| Influenza virus assembly: effect of influenza virus glycoproteins on the membrane association of M1 protein | Q33914921 | ||
| Analysis of in vivo dynamics of influenza virus infection in mice using a GFP reporter virus | Q33953302 | ||
| Influenza virus M2 protein has ion channel activity | Q34248853 | ||
| Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)--United States, 2012-13 influenza season | Q34294175 | ||
| Replication-competent influenza A viruses expressing a red fluorescent protein | Q35071285 | ||
| Development of a mouse-adapted live attenuated influenza virus that permits in vivo analysis of enhancements to the safety of live attenuated influenza virus vaccine | Q35110968 | ||
| A nuclear export signal in the matrix protein of Influenza A virus is required for efficient virus replication | Q35943682 | ||
| FluBlok, a recombinant hemagglutinin influenza vaccine | Q36251189 | ||
| Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults | Q36289253 | ||
| An overlapping protein-coding region in influenza A virus segment 3 modulates the host response | Q36554219 | ||
| A functionally defined model for the M2 proton channel of influenza A virus suggests a mechanism for its ion selectivity | Q36592280 | ||
| Four viral genes independently contribute to attenuation of live influenza A/Ann Arbor/6/60 (H2N2) cold-adapted reassortant virus vaccines | Q36826849 | ||
| The influenza virus M2 protein cytoplasmic tail interacts with the M1 protein and influences virus assembly at the site of virus budding | Q36933890 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 14 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | attenuated vaccine | Q1810913 |
| P304 | page(s) | 6291-6302 | |
| P577 | publication date | 2016-06-24 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Rearrangement of Influenza Virus Spliced Segments for the Development of Live-Attenuated Vaccines | |
| P478 | volume | 90 |
| Q52659466 | A Highly Potent and Broadly Neutralizing H1 Influenza-Specific Human Monoclonal Antibody. |
| Q60925671 | A Mechanism Underlying Attenuation of Recombinant Influenza A Viruses Carrying Reporter Genes |
| Q92340053 | A Novel Fluorescent and Bioluminescent Bireporter Influenza A Virus To Evaluate Viral Infections |
| Q38717627 | A live-attenuated influenza vaccine for H3N2 canine influenza virus. |
| Q40503815 | Canine influenza viruses with modified NS1 proteins for the development of live-attenuated vaccines |
| Q50054245 | Development of a novel equine influenza virus live-attenuated vaccine. |
| Q92538061 | Functional Characterization and Direct Comparison of Influenza A, B, C, and D NS1 Proteins in vitro and in vivo |
| Q40150645 | Functional Evolution of Influenza Virus NS1 Protein in Currently Circulating Human 2009 Pandemic H1N1 Viruses. |
| Q57093666 | Functional Evolution of the 2009 Pandemic H1N1 Influenza Virus NS1 and PA in Humans |
| Q41933705 | Influenza A Virus Studies in a Mouse Model of Infection. |
| Q61798670 | Mutation S110L of H1N1 Influenza Virus Hemagglutinin: A Potent Determinant of Attenuation in the Mouse Model |
| Q40399903 | NS1 Protein Amino Acid Changes D189N and V194I Affect Interferon Responses, Thermosensitivity, and Virulence of Circulating H3N2 Human Influenza A Viruses |
| Q37347309 | NS1 Protein Mutation I64T Affects Interferon Responses and Virulence of Circulating H3N2 Human Influenza A Viruses. |
| Q64116962 | Novel Approaches for The Development of Live Attenuated Influenza Vaccines |
| Q40052241 | Pandemic 2009 H1N1 Influenza Venus reporter virus reveals broad diversity of MHC class II-positive antigen-bearing cells following infection in vivo |
| Q28076140 | Reverse Genetics Approaches for the Development of Influenza Vaccines |
| Q57466491 | Temperature Sensitive Mutations in Influenza A Viral Ribonucleoprotein Complex Responsible for the Attenuation of the Live Attenuated Influenza Vaccine |
| Q38727207 | Temperature-Sensitive Live-Attenuated Canine Influenza Virus H3N8 Vaccine |
| Q40072930 | The K186E Amino Acid Substitution in the Canine Influenza Virus H3N8 NS1 Protein Restores Its Ability To Inhibit Host Gene Expression. |
| Q92964735 | Tyr82 Amino Acid Mutation in PB1 Polymerase Induces an Influenza Virus Mutator Phenotype |
| Q50308620 | Universal Vaccines and Vaccine Platforms to Protect against Influenza Viruses in Humans and Agriculture. |
Search more.